ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag drug safety microbiology evolution

Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
A needle drawing up fluid from an unlabeled vial.
Cancer Vaccination as a Promising New Treatment Against Tumors
Shelby Bradford, PhD | Mar 15, 2024 | 10+ min read
Vaccination has beaten back infections for more than a century. Now, it may be the next big step in battling cancer.
Speaking of Microbiology
Tanya Lewis and Tracy Vence | Jun 21, 2016 | 2 min read
A selection of notable quotes from the American Society for Microbiology’s annual meeting
bacteria inside a biofilm
How Bacterial Communities Divvy up Duties
Holly Barker, PhD | Jun 1, 2023 | 10+ min read
Biofilms are home to millions of microbes, but disrupting their interactions could produce more effective antibiotics.
microbiome drugs
How the Microbiome Influences Drug Action
Shawna Williams | Jul 15, 2019 | 10+ min read
Through their effects on metabolism and immunity, bacteria in the gut affect whether medications will be effective for a given patient.
illustration of neurons in blue with synapses lighting up
Gut Molecule Linked to Decreased Myelination in Mouse Brains
Angie Voyles Askham, Spectrum | Feb 17, 2022 | 4 min read
A study shows that a molecule produced by intestinal microbes can enter the brain and that its presence is also associated with altered brain connectivity.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Updated Sept 1
coronavirus pandemic news articles covid-19 sars-cov-2 virology research science
Follow the Coronavirus Outbreak
The Scientist | Feb 20, 2020 | 10+ min read
Saliva tests screen staff and students at University of Illinois; Study ranks species most susceptible to SARS-CoV-2 infection; COVID-19 clinical trials test drugs that inhibit kinin system
monoclonal antibody antibodies sars-cov-2 covid-19 coronavirus pandemic eli lilly receptor binding domain spike protein
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020 | 8 min read
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
Companies Seeking Solutions To Emerging Drug Resistance
Stephen Hoffert | Apr 12, 1998 | 10 min read
PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new

Run a Search

ADVERTISEMENT